{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-023288","form_type":"8-K","ticker":"OCGN","cik":"0001372299","company_name":"Ocugen, Inc.","filed_at":"2026-03-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.934276+00:00","generated_at":"2026-05-15T21:35:00.497360+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Ocugen Q4 2025 net loss $0.06/share; OCU400 Phase 3 enrollment complete; cash $18.9M","bullets":["Fourth quarter 2025 net loss $0.06 per share (vs $0.05 Q4 2024); full year net loss $0.23 per share (vs $0.20).","Cash and restricted cash $18.9M at Dec 31, 2025 ($58.8M year-end 2024); January 2026 raised $22.5M via stock offering led by RTW Investments.","OCU400 Phase 3 liMeliGhT trial for retinitis pigmentosa completed enrollment (140 patients); topline data expected Q1 2027.","OCU410ST Phase 2/3 GARDian trial nearing enrollment completion; interim data Q3 2026; OCU410 Phase 2 showed 46% lesion growth reduction.","Exclusive Korean rights to OCU400 licensed to Kwangdong Pharmaceutical with upfront fees and milestones."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-023288","json":"https://secwatch.observer/filing/0001104659-26-023288.json","markdown":"https://secwatch.observer/filing/0001104659-26-023288.md","text":"https://secwatch.observer/filing/0001104659-26-023288.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1372299/000110465926023288/0001104659-26-023288-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1372299/000110465926023288/tm267731d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T21:35:00.497360+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}